Patents by Inventor Giulio Draetta
Giulio Draetta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140011748Abstract: This present invention provides methods of treating of accessing/monitoring the responsiveness of a cancer cell to JNK inhibitor therapy.Type: ApplicationFiled: January 19, 2012Publication date: January 9, 2014Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Lynda Chin, Ronald A. Depinho, Giulio Draetta, Timothy P. Heffernan
-
Patent number: 7566455Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, of novel protein-protein interactions between certain cellular proteins, referred to herein as “E6AP-binding proteins” or “E6AP-BPs”, and the cellular protein E6AP, the latter of which is a component of a ubiquitin-ligase (E3) enzyme. The association of E6AP and the subject E6AP-binding proteins implicates the E6AP-binding proteins in a number of basic cellular functions, such as regulation of gene expression, regulation of the cell-cycle, modification of cell surface receptors, biogenesis of ribosomes, and DNA repair. One of the E6AP-binding proteins shares certain homology with the papillomavirus E6 protein, which also binds E6AP.Type: GrantFiled: June 7, 1995Date of Patent: July 28, 2009Assignee: GPC Biotech, Inc.Inventors: Peggy L. Beer-Romero, Giulio Draetta, Mark Rolfe
-
Publication number: 20030104362Abstract: The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.Type: ApplicationFiled: May 5, 1998Publication date: June 5, 2003Inventors: GUILLAUME COTTAREL, VERONIQUE DAMAGNEZ, GIULIO DRAETTA
-
Patent number: 6251585Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.Type: GrantFiled: April 24, 1995Date of Patent: June 26, 2001Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez
-
Patent number: 6068982Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.Type: GrantFiled: December 17, 1996Date of Patent: May 30, 2000Assignee: Mitotix, Inc.Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
-
Patent number: 6015692Abstract: The present invention relates to the discovery in mammalian cells, particularly human cells, of a novel CDK-binding protein, referred to herein as "cdc37". As described herein, this protein functions to facilitate activation and accordingly finctions in the modulation of cell-cycle progression, and therefore ultimately of cell growth and differentiation. Moreover, binding data indicated that cdc37 may function coordinately with other cell-cycle regulatory proteins, such as of cyclin-dependent kinases (CDKs), src, p53 and erk kinases.Type: GrantFiled: May 9, 1997Date of Patent: January 18, 2000Assignee: Mitotix, Inc.Inventors: Jeno Gyuris, Lou Lamphere, Giulio Draetta
-
Patent number: 5981699Abstract: The present invention concerns a novel human ubiquitin-conjugating enzyme which is implicated in the ubiquitin-mediated inactivation of cell-cycle regulatory proteins, partucularly p53. The present invention makes available diagnostic and therapeutic assays and reagents for detecting and treating transformed cells, such as may be useful in the detection of cancer. The present invention also provides reagents for altering the normal regulation cell proliferation in untransformed cells, such as by upregulating certain cell-cycle checkpoints, e.g. to protect normal cells against DNA damaging reagents.Type: GrantFiled: May 23, 1994Date of Patent: November 9, 1999Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Mark Rolfe, Jens W. Eckstein
-
Patent number: 5968761Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignee: Mitotix, Inc.Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
-
Patent number: 5858987Abstract: The present invention relates to the discovery that antisense nucleic acids complimentary to an E6AP gene can be used to regulate cellular p53 levels. In general the invention features E6AP antisense constructs which, by inhibiting E6AP activity, can modulate cellular p53 levels in both p53+ transformed cells and in normal cells. The invention also provides methods for treating papillomavirus (PV) induced condition, methods for regulating cellular p53 levels and methods for regulating cellular proliferation.Type: GrantFiled: May 5, 1995Date of Patent: January 12, 1999Assignee: Mitotix, Inc.Inventors: Peggy L. Beer-Romero, Giulio Draetta, Mark Rolfe
-
Patent number: 5801015Abstract: The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.Type: GrantFiled: June 5, 1995Date of Patent: September 1, 1998Assignee: Mitotix, Inc.Inventors: Guillaume Cottarel, Veronique Damagnez, Giulio Draetta
-
Patent number: 5756671Abstract: The present invention relates to the discovery in mammalian cells, particularly human cells, of a novel CDK-binding protein, referred to herein as "cdc37". As described herein, this protein functions to facilitate activation and accordingly functions in the modulation of cell-cycle progression, and therefore ultimately of cell growth and differentiation. Moreover, binding data indicated that cdc37 may function coordinately with other cell-cycle regulatory proteins, such as of cyclin-dependent kinases (CDKs), src, p53 and erk kinases.Type: GrantFiled: April 1, 1996Date of Patent: May 26, 1998Assignee: Mitotix, Inc.Inventors: Jeno Gyuris, Lou Lamphere, Giulio Draetta
-
Patent number: 5744343Abstract: The present invention concerns three ubiquitin-conjugating enzymes.Type: GrantFiled: September 13, 1994Date of Patent: April 28, 1998Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Mark Rolfe, Jens W. Eckstein, Guillaume Cottarel
-
Patent number: 5691147Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which can associate with the human cyclin dependent kinase 4 (CDK4).Type: GrantFiled: June 2, 1994Date of Patent: November 25, 1997Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Jeno Gyuris
-
Patent number: 5443962Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors, especially inhibitors of cdc25 phosphatase. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.Type: GrantFiled: June 4, 1993Date of Patent: August 22, 1995Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez